Back to search results

Home-based PrEP Monitoring for HIV Prevention

This study is testing a new way to provide PrEP (Pre-exposure Prophylaxis), a medicine that prevents HIV. It's called home-based PrEP (HB-PrEP) monitoring. This involves you collecting blood and other samples at home, and having follow-up appointments through telehealth (like video calls). The study wants to see if HB-PrEP helps more people stay on their PrEP treatment compared to standard care. You might be able to join if you are 18 or older, live in Washington State, can speak English or Spanish, and are eligible for PrEP according to King County criteria. The main goal is to see how many people continue their PrEP treatment for 18 months.

Study design
This is an interventional study planning to enroll 458 participants. It is a randomized controlled trial, meaning participants will be assigned by chance to either home-based PrEP care or standard care.
What's involved
Participants will self-collect blood specimens using Tasso devices and have telehealth follow-up appointments. You will need to adhere to study procedures.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, PrEP retention, is measured at 18 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05856942

Hybrid Evaluation of a Home-based HIV Pre-exposure Prophylaxis Program

UNKNOWN
NAAges 18+InterventionalHealth services
University of Washington
~458 participants
Updated 2024-05-10 on ClinicalTrials.gov
What's tested:Health service - home-based PrEP monitoring

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
PrEP retention
Measured over 18 months

Conditions

HIV Prevention
Pre-exposure Prophylaxis
STI

Explore related trials

Stroke prevention

Where it's being run

1 sites across 1 states
Washington1

Study leadership

  • Chase Cannon, MD, MPH · PRINCIPAL_INVESTIGATOR · University of Washington

Who to contact

Chase Cannon, MD, MPH
[email protected]
206-744-4393
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Must be eligible to receive PrEP per PHSKC criteria
Age ≥18 years
Washington State resident
Ability to speak, understand and read/write in English or Spanish
Willing to provide contact information
Willing to be randomized and adhere to study procedures

Exclusion

Recent (\<4 weeks) "high risk" HIV exposure while off PrEP or symptoms of acute HIV
No mailing address to receive sampling kits
No working telephone number
No smartphone or other device with internet access
History of a bleeding disorder, or current or recent (≤7 days) use of anticoagulant medications
Pregnancy

What this trial measures

  • PrEP retention18 months

    Proportion of participants who successfully complete triannual monitoring tests and visits to receive a renewed PrEP prescription